CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Caspofungindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01165320
NCT01165320Phase 2Completed
CompareCT.gov

A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections

Merck Sharp & Dohme LLC·interventional·Posted Jul 19, 2010·Updated Aug 27, 2018

In Brief

A Phase 2 clinical trial evaluating Caspofungin for Candidiasis, Esophageal and 2 related conditions. Completed, enrolled 20 participants.

Detailed Summary

The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCandidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 19, 2010
Enrollment StartJul 6, 2010
Primary CompletionSep 17, 2013
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 16.0 years ago

Interventions

Caspofungindrug